Workflow
青松股份(300132):收入回暖,盈利大幅改善

Investment Rating - The report maintains an "Outperform" rating for the company, with a target price of RMB 10.50 based on a target PE of 35x for 2026 [4][13]. Core Insights - The company has turned around after four years of adjustments, entering a growth phase with improved revenue and profit [4][14]. - For the first three quarters of 2025, revenue, net profit attributable to shareholders, and recurring net profit were RMB 1.55 billion, RMB 111 million, and RMB 75 million, representing year-on-year increases of 12.00%, 246.98%, and 146.48% respectively [4][14]. - The mask category has shown significant growth, leading the overall revenue increase, while the company is expected to gain market share as the industry recovers from a downturn [4][16]. Financial Summary - Revenue projections for 2025-2027 are RMB 2.185 billion, RMB 2.446 billion, and RMB 2.689 billion, with respective growth rates of 12.6%, 11.9%, and 9.9% [3][5]. - Net profit attributable to shareholders is forecasted to be RMB 142 million, RMB 154 million, and RMB 203 million for 2025-2027, with growth rates of 160.0%, 8.5%, and 31.4% [3][5]. - The company's gross profit margin for Q3 2025 was 21.77%, up 2.83% year-on-year, indicating improved operational efficiency [4][14]. Product Category Performance - In H1 2025, revenue from masks, skincare, and wipes was RMB 450 million, RMB 323 million, and RMB 125 million, with year-on-year growth of 21%, 7%, and a decline of 9% respectively [4][15]. - The gross profit margins for masks, skincare, and wipes were 19.01%, 16.67%, and 13.45%, reflecting improvements due to increased capacity utilization and revenue growth [4][15]. Industry Outlook - The cosmetics industry has faced a downturn since 2022, leading to intensified competition and the exit of smaller players, which is expected to benefit leading companies like the report's subject [4][16]. - The company's subsidiary, North Bell, is positioned to attract quality brands and gain market share due to its scale advantages and ongoing R&D investments [4][16].